January 23, 2018 / 11:52 AM / in 10 minutes BRIEF-Johnson & Johnson Reports 2017 Q4 Loss Of $3.99 Per Share Reuters Staff 
Jan 23 (Reuters) - Johnson & Johnson: * REPORTS 2017 FOURTH-QUARTER RESULTS: * SEES FY 2018 ADJUSTED EARNINGS PER SHARE $8.00 TO $8.20 * SEES FY 2018 SALES $80.6 BILLION TO $81.4 BILLION * SEES FY 2018 SALES UP 3.5 TO 4.5 PERCENT 
* J&J - 2017 FOURTH-QUARTER SALES OF $20.2 BILLION INCREASED 11.5%; EPS WAS A LOSS OF $3.99 
* Q4 EARNINGS PER SHARE VIEW $1.72, REVENUE VIEW $20.07 BILLION -- THOMSON REUTERS I/B/E/S * J&J - ADJUSTED 2017 FOURTH-QUARTER EPS WAS $1.74 
* J&J - ‍​ COMPANY RECORDS SPECIAL ITEM CHARGE OF APPROXIMATELY $13.6 BILLION RELATED TO RECENTLY ENACTED TAX LEGISLATION 
* J&J - EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON OPERATIONAL BASIS, WORLDWIDE SALES FOR Q4 INCREASED 4.2% 
* Q4 EARNINGS PER SHARE VIEW $1.72, REVENUE VIEW $20.07 BILLION -- THOMSON REUTERS I/B/E/S 
* J&J - QTRLY WORLDWIDE CONSUMER SALES OF $3,540 MILLION VERSUS $3,432 MILLION 
* J&J QTRLY WORLDWIDE VELCADE SALES $271 MILLION VERSUS $273 MILLION IN Q3 2017 
* J&J - QTRLY WORLDWIDE PHARMACEUTICAL SALES OF $9,681 MILLION VERSUS $8,232 MILLION 
* J&J - EXCLUDING NET IMPACT OF ACQUISITIONS, DIVESTITURES, ON OPERATIONAL BASIS, DOMESTIC SALES ROSE 4.1% AND INTERNATIONAL SALES ROSE 4.3% IN QUARTER 
* FY2018 EARNINGS PER SHARE VIEW $7.87, REVENUE VIEW $80.70 BILLION -- THOMSON REUTERS I/B/E/S 
* J&J QTRLY WORLDWIDE ZYTIGA SALES $755 MILLION VERSUS $669 MILLION IN Q3 2017 
* J&J - QTRLY WORLDWIDE MEDICAL DEVICES SALES OF $6,974 MILLION VERSUS $6,442 MILLION 
* J&J QTRLY WORLDWIDE REMICADE SALES $1,466 MILLION VERSUS $1,647 MILLION IN Q3 
* J&J QTRLY WORLDWIDE INVOKANA/INVOKAMET SALES $267 MILLION VERSUS $265 MILLION IN Q3 2017 Source text for Eikon: Further company coverage: